Recurrence and survival in high-intermediate risk endometrial cancers with isolated tumor cell lymph node metastasis
In this retrospective study, there was no significant difference in survival for patients with HIR endometrial cancer and ITC SLNs treated with either EBRT/VBT or CRT. Patients with three or more HIR risk factors remain at risk for recurrence despite CRT. Further prospective studies should assess recurrence risk factors in HIR EC with ITC, likely incorporating standard histopathology and molecular profiles to tailor adjuvant CRT.
Authors
- Jianbin Zhu (ORCID: https://orcid.org/0000-0002-4716-6628)
- Ahmad Awada (ORCID: https://orcid.org/0000-0001-7412-9163)
- James E. Kendrick (ORCID: https://orcid.org/0000-0003-3925-1715)
- Robert W. Holloway (ORCID: https://orcid.org/0000-0002-3121-4605)
- Sarfraz Ahmad (ORCID: https://orcid.org/0000-0002-5180-0409)
- Theresa Kuhn
- Fernando O. Recio
- Nathalie D. McKenzie (ORCID: https://orcid.org/0000-0002-9550-3457)
Institutions
- Florida Hospital Cancer Institute (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.gore.2025.101684
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00